| 7/21/2021 |
Goldman Sachs Group Inc. Raises Holdings in NeoGenomics, Inc. (NASDAQ:NEO) |
The Markets Daily |
Goldman Sachs Group Inc. boosted its stake in NeoGenomics, Inc. (NASDAQ:NEO) by 48.4% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 293,616 shares of the medical research company’s stock after purchasing an additional 95,696 shares during the period. Goldman Sachs Group Inc. owned about 0.25% of NeoGenomics worth $14,161,000 at the end of the most recent ... |
| 7/21/2021 |
Goldman Sachs Group Inc. Raises Stock Position in NeoGenomics, Inc. (NASDAQ:NEO) |
Dakota Financial News |
Goldman Sachs Group Inc. lifted its holdings in NeoGenomics, Inc. (NASDAQ:NEO) by 48.4% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 293,616 shares of the medical research company’s stock after buying an additional 95,696 shares during the period. Goldman Sachs Group Inc.’s holdings in NeoGenomics were worth $14,161,000 at the end of the ... |
| 7/20/2021 |
Dimensional Fund Advisors LP Sells 273,883 Shares of NeoGenomics, Inc. (NASDAQ:NEO) |
baseballnewssource.com |
Dimensional Fund Advisors LP lessened its stake in shares of NeoGenomics, Inc. (NASDAQ:NEO) by 22.9% during the first quarter, according to the company in its most recent disclosure with the SEC. The fund owned 920,316 shares of the medical research company’s stock after selling 273,883 shares during the quarter. Dimensional Fund Advisors LP owned approximately 0.78% of NeoGenomics worth $44,437,000 as of its most recent SEC filing. Several ... |
| 7/20/2021 |
Dimensional Fund Advisors LP Sells 273,883 Shares of NeoGenomics, Inc. (NASDAQ:NEO) |
com-unik.info |
Dimensional Fund Advisors LP lessened its position in NeoGenomics, Inc. (NASDAQ:NEO) by 22.9% during the first quarter, Holdings Channel.com reports. The fund owned 920,316 shares of the medical research company’s stock after selling 273,883 shares during the period. Dimensional Fund Advisors LP’s holdings in NeoGenomics were worth $44,437,000 at the end of the most recent quarter. Several other institutional investors and hedge funds also recently made changes ... |
| 7/20/2021 |
Greater Fort Myers Chamber to explore unique ways companies help their community at Aug. 18 luncheon |
aboveboardchamber.com |
... professionals, who have implemented creative ways to serve their community. The five guest speakers include Julio Barina, firm partner with Markham Norton Mosteller Wright & Company, P.A.; Brandy Lai, senior director of human resources of NeoGenomics Laboratories; Joe Ramsay, owner, and Rusty Smith, marketing manager of Pit Stop Auto Repair; and Denise Spence, IT programs manager for Dunbar High School. During the panel, Lai and Spence will discuss NeoGenomics ’ collaboration ... |
| 7/19/2021 |
American Capital Management Inc. Has $11.33 Million Stake in NeoGenomics, Inc. (NASDAQ:NEO) |
slatersentinel.com |
American Capital Management Inc. decreased its position in shares of NeoGenomics, Inc. (NASDAQ:NEO) by 14.0% in the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 234,868 shares of the medical research company’s stock after selling 38,232 shares during the period. American Capital Management Inc.’s holdings in NeoGenomics were worth $11,328,000 at the end of the most recent reporting period. Several other hedge funds and other institutional investors ... |
| 7/18/2021 |
NeoGenomics, Inc. (NASDAQ:NEO) Forecasted to Post Q2 2021 Earnings of ($0.10) Per Share |
slatersentinel.com |
NeoGenomics, Inc. (NASDAQ:NEO) – Stock analysts at SVB Leerink dropped their Q2 2021 earnings per share estimates for NeoGenomics in a research report issued on Wednesday, July 14th. SVB Leerink analyst P. Souda now anticipates that the medical research company will post earnings per share of ($0.10) for the quarter, down from their previous forecast of ($0.08). SVB Leerink also issued estimates for NeoGenomics ’ Q3 2021 earnings at ... |
| 7/18/2021 |
Brokers Set Expectations for NeoGenomics, Inc.'s Q2 2021 Earnings (NASDAQ:NEO) |
rivertonroll.com |
NeoGenomics, Inc. (NASDAQ:NEO) – Equities research analysts at SVB Leerink decreased their Q2 2021 earnings per share (EPS) estimates for NeoGenomics in a note issued to investors on Wednesday, July 14th. SVB Leerink analyst P. Souda now anticipates that the medical research company will post earnings of ($0.10) per share for the quarter, down from their previous forecast of ($0.08). SVB Leerink also issued estimates for NeoGenomics’ Q3 ... |
| 7/18/2021 |
Nuveen Asset Management LLC Purchases 104,285 Shares of NeoGenomics, Inc. (NASDAQ:NEO) |
baseballnewssource.com |
Nuveen Asset Management LLC increased its position in shares of NeoGenomics, Inc. (NASDAQ:NEO) by 13.4% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 883,652 shares of the medical research company’s stock after purchasing an additional 104,285 shares during the quarter. Nuveen Asset Management LLC owned 0.75% of NeoGenomics worth $42,619,000 at the end of the most ... |
| 7/18/2021 |
Nuveen Asset Management LLC Buys 104,285 Shares of NeoGenomics, Inc. (NASDAQ:NEO) |
com-unik.info |
Nuveen Asset Management LLC boosted its stake in NeoGenomics, Inc. (NASDAQ:NEO) by 13.4% in the 1st quarter, Holdings Channel reports. The firm owned 883,652 shares of the medical research company’s stock after acquiring an additional 104,285 shares during the quarter. Nuveen Asset Management LLC’s holdings in NeoGenomics were worth $42,619,000 at the end of the most recent reporting period. A number of other hedge funds and other ... |
| 7/17/2021 |
NeoGenomics, Inc. (NASDAQ:NEO) Forecasted to Post Q2 2021 Earnings of ($0.10) Per Share - Ticker Report |
Ticker Report |
NeoGenomics, Inc. (NASDAQ:NEO) – Equities research analysts at SVB Leerink lowered their Q2 2021 EPS estimates for NeoGenomics in a report released on Wednesday, July 14th. SVB Leerink analyst P. Souda now anticipates that the medical research company will earn ($0.10) per share for the quarter, down from their previous forecast of ($0.08). SVB Leerink also issued estimates for NeoGenomics ’ Q3 2021 earnings at ($0.10) EPS and FY2021 ... |
| 7/17/2021 |
Cancer/Tumor Profiling Market 2021 Research including Growth Factors, Global Survey, Development Strategy: |
PRSync |
... Central & South America. Request Sample Copy of this Report at: https://www.datalibraryresearch.com/sample-request/cancer-tumor-profiling-market-2370 utmsource=prysnc&utmmedium=63 Key Strategic Players: Illumina, Inc. (US), QIAGEN N.V. (Germany), NeoGenomics Laboratories, Inc. (US), HTG Molecular Diagnostics, Inc. (US), Genomic Health Inc. (US), Caris Life Sciences (US), Helomics Corporation (US), NanoString Technologies, Inc. (US), Sysmex Corporation (Japan), Ribomed Biotechnologies, Inc. (US), Guardant Health, Inc. (US), Foundation ... |
| 7/17/2021 |
NeoGenomics, Inc. (NASDAQ:NEO) Shares Purchased by Thrivent Financial for Lutherans - American Banking News |
American Banking News |
Thrivent Financial for Lutherans increased its holdings in shares of NeoGenomics , Inc. (NASDAQ:NEO) by 4.5% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 96,062 shares of the medical research company’s stock after acquiring an additional 4,160 shares during the quarter. Thrivent Financial for Lutherans owned about 0.08% of NeoGenomics worth $4,633,000 at the end of the most ... |
| 7/17/2021 |
NeoGenomics, Inc. (NASDAQ:NEO) Shares Purchased by Thrivent Financial for Lutherans |
baseballnewssource.com |
Thrivent Financial for Lutherans increased its holdings in shares of NeoGenomics , Inc. (NASDAQ:NEO) by 4.5% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 96,062 shares of the medical research company’s stock after acquiring an additional 4,160 shares during the quarter. Thrivent Financial for Lutherans owned about 0.08% of NeoGenomics worth $4,633,000 at the end of the most ... |
| 7/16/2021 |
NeoGenomics – Consensus Indicates Potential 33.4% Upside |
directorstalkinterviews.com |
... with Inivata Limited; and has collaboration with Elevation Oncology to expand genomic testing for NRG1 fusions across solid tumors. The company was founded in 2001 and is headquartered in Fort Myers, Florida.This article NeoGenomics – Consensus Indicates Potential 33.4% Upside first appeared on DirectorsTalk Interviews ... |
| 7/16/2021 |
NeoGenomics, Inc. to Post Q2 2021 Earnings of ($0.10) Per Share, SVB Leerink Forecasts (NASDAQ:NEO) - American Banking News |
American Banking News |
NeoGenomics, Inc. (NASDAQ:NEO) – Stock analysts at SVB Leerink reduced their Q2 2021 earnings per share (EPS) estimates for shares of NeoGenomics in a research report issued on Wednesday, July 14th. SVB Leerink analyst P. Souda now forecasts that the medical research company will post earnings of ($0.10) per share for the quarter, down from their previous forecast of ($0.08). SVB Leerink also issued estimates for NeoGenomics ’ Q3 ... |
| 7/16/2021 |
JS Capital Management LLC Takes Position in NeoGenomics, Inc. (NASDAQ:NEO) |
baseballnewssource.com |
JS Capital Management LLC acquired a new stake in NeoGenomics, Inc. (NASDAQ:NEO) during the first quarter, Holdings Channel reports. The institutional investor acquired 6,100 shares of the medical research company’s stock, valued at approximately $294,000. Several other hedge funds and other institutional investors have also bought and sold shares of NEO. Teacher Retirement System of Texas increased its holdings in NeoGenomics by 61.9% during the fourth quarter. Teacher ... |
| 7/16/2021 |
JS Capital Management LLC Makes New $294,000 Investment in NeoGenomics, Inc. (NASDAQ:NEO) - The Cerbat Gem |
thecerbatgem.com |
JS Capital Management LLC bought a new position in NeoGenomics, Inc. (NASDAQ:NEO) in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 6,100 shares of the medical research company’s stock, valued at approximately $294,000.Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Bedel Financial Consulting Inc. bought a new ... |
| 7/16/2021 |
Pathological Examination Market will be able to get the maximum revenue in 2021-2028 | 3DHISTECH Ltd, Healio, Abbott Pathology, NeoGenomics Laboratories |
PRSync |
Pathological Examination Market will be able to get the maximum revenue in 2021-2028 3DHISTECH Ltd, Healio, Abbott Pathology, NeoGenomics Laboratories The report, titled "Global Pathological Examination Market", is a unique market research that provides the most up-to-date detailed information and comprehensive market analysis. It provides a complete market overview with detailed understanding of key factors including the current market situation, potential market size, volume and dynamics. This research ... |
| 7/16/2021 |
NEOGENOMICS INC: a Form 8-K/A has been Filed with the SEC |
creditriskmonitor.com |
Help CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals. Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue. We also offer solutions that can help ease private company financial risk assessment. Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help ... |